IRIS Accounts Production v24.1.0.578 10409217 director 1.11.22 31.10.23 31.10.23 false true false false false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh104092172022-10-31104092172023-10-31104092172022-11-012023-10-31104092172021-10-31104092172021-11-012022-10-31104092172022-10-3110409217ns15:EnglandWales2022-11-012023-10-3110409217ns14:PoundSterling2022-11-012023-10-3110409217ns10:Director12022-11-012023-10-3110409217ns10:PrivateLimitedCompanyLtd2022-11-012023-10-3110409217ns10:Micro-entities2022-11-012023-10-3110409217ns10:AuditExempt-NoAccountantsReport2022-11-012023-10-3110409217ns10:FullAccounts2022-11-012023-10-3110409217ns10:RegisteredOffice2022-11-012023-10-3110409217ns5:CurrentFinancialInstruments2023-10-3110409217ns5:CurrentFinancialInstruments2022-10-31104092171ns10:Director12022-10-31104092171ns10:Director12021-10-31104092171ns10:Director12022-11-012023-10-31104092171ns10:Director12021-11-012022-10-31104092171ns10:Director12023-10-31104092171ns10:Director12022-10-31
REGISTERED NUMBER: 10409217 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 October 2023

for

Nj Biopharma Consulting Limited

Nj Biopharma Consulting Limited (by shares) (Registered number: 10409217)






Contents of the Financial Statements
for the Year Ended 31 October 2023




Page

Company Information 1

Balance Sheet 2


Nj Biopharma Consulting Limited (by shares)

Company Information
for the Year Ended 31 October 2023







DIRECTOR: Dr N Johnson





REGISTERED OFFICE: 66 Kenilworth Road
Sale
Greater Manchester
M33 5DB





REGISTERED NUMBER: 10409217 (England and Wales)






Nj Biopharma Consulting Limited (by shares) (Registered number: 10409217)

Balance Sheet
31 October 2023

31.10.23 31.10.22
£    £    £    £   
FIXED ASSETS 24,006 24,536

CURRENT ASSETS 293,611 205,774

CREDITORS
Amounts falling due within one year (84,235 ) (62,033 )
NET CURRENT ASSETS 209,376 143,741
TOTAL ASSETS LESS CURRENT
LIABILITIES

233,382

168,277

CAPITAL AND RESERVES 233,382 168,277

NOTES TO THE FINANCIAL STATEMENTS

1. AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the year was 4 (2022 - 2 ) .

2. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 October 2023 and 31 October 2022:

31.10.23 31.10.22
£    £   
Dr N Johnson
Balance outstanding at start of year - 3,301
Amounts advanced 72,111 -
Amounts repaid - (3,301 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 72,111 -



The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 October 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Nj Biopharma Consulting Limited (by shares) (Registered number: 10409217)

Balance Sheet - continued
31 October 2023


The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the director and authorised for issue on 17 January 2024 and were signed by:





Dr N Johnson - Director